|
1
|
DeSantis CE, Lin CC, Mariotto AB, Siegel
RL, Stein KD, Kramer JL, Alteri R, Robbins AS and Jemal A: Cancer
treatment and survivorship statistics, 2014. CA Cancer J Clin.
64:252–271. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nyquist MD and Dehm SM: Interplay between
genomic alterations and androgen receptor signaling during prostate
cancer development and progression. Horm Cancer. 4:61–69. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hamid AR, Hoogland AM, Smit F, Jannink S,
van Rijt-van de Westerlo C, Jansen CF, van Leenders GJ, Verhaegh GW
and Schalken JA: The role of HOXC6 in prostate cancer development.
Prostate. 75:1868–1876. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Crawford ED, Stone NN, Evan YY, Koo PJ,
Freedland SJ, Slovin SF, Gomella LG, Berger ER, Keane TE, Sieber P,
et al: Challenges and recommendations for early identification of
metastatic disease in prostate cancer. Urology. 83:664–669. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ruddon RW: Cancer biology. Oxford
University Press; Oxford: 2007
|
|
6
|
Schröder FH, Hugosson J, Roobol MJ,
Tammela TL, Zappa M, Nelen V, Kwiatkowski M, Lujan M, Määttänen L,
Lilja H, et al: Screening and prostate cancer mortality: Results of
the European randomised study of screening for prostate cancer
(ERSPC) at 13 years of follow-up. Lancet. 384:2027–2035. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Szczyrba J, Löprich E, Wach S, Jung V,
Unteregger G, Barth S, Grobholz R, Wieland W, Stöhr R, Hartmann A,
et al: The microRNA profile of prostate carcinoma obtained by deep
sequencing. Mol Cancer Res. 8:529–538. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Xu J, Zhu X, Wu L, Yang R, Yang Z, Wang Q
and Wu F: MicroRNA-122 suppresses cell proliferation and induces
cell apoptosis in hepatocellular carcinoma by directly targeting
Wnt/β-catenin pathway. Liver Int. 32:752–760. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang Y, Sturgis EM, Sun Y, Sun C, Wei Q,
Huang Z and Li G: A functional variant at miRNA-122 binding site in
IL-1α 3′ UTR predicts risk and HPV-positive tumours of
oropharyngeal cancer. Eur J Cancer. 51:1415–1423. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kroiss A, Vincent S, Decaussin-Petrucci M,
Meugnier E, Viallet J, Ruffion A, Chalmel F, Samarut J and Allioli
N: Androgen-regulated microRNA-135a decreases prostate cancer cell
migration and invasion through downregulating ROCK1 and ROCK2.
Oncogene. 34:2846–2855. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang C, Zhang S, Zhang Z, He J, Xu Y and
Liu S: ROCK has a crucial role in regulating prostate tumor growth
through interaction with c-Myc. Oncogene. 33:5582–5591. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hart M, Nolte E, Wach S, Szczyrba J,
Taubert H, Rau TT, Hartmann A, Grässer FA and Wullich B:
Comparative microRNA profiling of prostate carcinomas with
increasing tumor stage by deep sequencing. Mol Cancer Res.
12:250–263. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xu L, Zhong J, Guo B, Zhu Q, Liang H, Wen
N, Yun W and Zhang L: miR-96 promotes the growth of prostate
carcinoma cells by suppressing MTSS1. Tumour Biol. 37:12023–12032.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bakkar A, Alshalalfa M, Petersen LF,
Abou-Ouf H, Al-Mami A, Hegazy SA, Feng F, Alhajj R, Bijian K,
Alaoui-Jamali MA and Bismar TA: microRNA 338-3p exhibits tumor
suppressor role and its down-regulation is associated with adverse
clinical outcome in prostate cancer patients. Mol Biol Rep.
43:229–240. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Guo J, Wang M and Liu X: MicroRNA-195
suppresses tumor cell proliferation and metastasis by directly
targeting BCOX1 in prostate carcinoma. J Exp Clin Cancer Res.
34:912015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
El-Abd NE, Fawzy NA, El-Sheikh SM and
Soliman ME: Circulating miRNA-122, miRNA-199a, and miRNA-16 as
biomarkers for early detection of hepatocellular carcinoma in
egyptian patients with chronic hepatitis C virus infection. Mol
Diagn Ther. 19:213–220. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li M, Ke J, Wang Q, Qian H, Yang L, Zhang
X, Xiao J, Ding H, Shan X, Liu Q, et al: Upregulation of ROCK2 in
gastric cancer cell promotes tumor cell proliferation, metastasis
and invasion. Clin Exp Med. 17:519–529. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang W, Zhou X and Wei M: MicroRNA-144
suppresses osteosarcoma growth and metastasis by targeting ROCK1
and ROCK2. Oncotarget. 6:10297–10308. 2015.PubMed/NCBI
|
